Skip to content

Medical-device intelligence

MMW: System, Test, Tumor Marker, Monitoring, Bladder

FDA product code MMW: System, Test, Tumor Marker, Monitoring, Bladder. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
MMW
FDA device name
System, Test, Tumor Marker, Monitoring, Bladder
Device class
2
Regulation number
866.6010
Medical specialty
Immunology
Review panel
IM

The source does not provide a definition for this entry. Consult the FDA classification and regulation reference for further detail.

Explore immunology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

9 clearance records and 1 recall records in the covered releases, across 5 source company names and 1 product codes. Dated history runs from Apr 16, 1997 to May 4, 2023.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
MMW · System, Test, Tumor Marker, Monitoring, Bladder91

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

10 matching records
Device / recordCompany in FDA recordSourceSource date
Bladder EpiCheck DNA extraction kit, NX899090-01C, Bladder EpiCheck test kit, NX899090-02C, Bladder EpiCheck Software, NX899090-03CK203245 · MMWNucleix , Ltd.510(k)May 4, 2023FDA decision date
ProbeChek Vysis UroVysion Control Slides, for Fluorescence in situ Hybridization (FISH) using Vysis UroVysion Bladder Recurrence Kit; an invitro …Z-0640-04 · MMWVysisRecallJul 20, 2004FDA classification date
MODIFICATION TO VYSIS UROVYSION BLADDER CANCER RECURRENCE TESTK033982 · MMWVysis510(k)Jan 22, 2004FDA decision date
NMP22 BLADDERCHEK KIT, NMP22 CONTROL KITK021231 · MMWMatritech, Inc.510(k)Jul 30, 2002FDA decision date
UROVYSION BLADDER CANCER RECURRENCE KITK013785 · MMWVysis510(k)Feb 8, 2002FDA decision date
VYSIS UROVYSION BLADDER CANCER RECURRENCE KITK011031 · MMWVysis510(k)Aug 3, 2001FDA decision date
BTA STAT TEST PRESCRIPTION HOME USEK974845 · MMWBard Diagnostic Sciences,Inc.510(k)Dec 8, 1998FDA decision date
BARD BTA TRAK TESTK971402 · MMWBard Diagnostic Sciences,Inc.510(k)Apr 15, 1998FDA decision date
AURA TEK FDPK970353 · MMWPerimmune, Inc.510(k)Apr 30, 1997FDA decision date
BARD AND BTA TESTK964151 · MMWBard Diagnostic Sciences,Inc.510(k)Apr 16, 1997FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗